Hagens Berman is investigating Alignment Healthcare (ALHC) following whistleblower allegations that the company engaged in accounting irregularities by misclassifying operating expenses as capital expenditures to inflate EBITDA and financial results for 2024-2025. The disclosure caused ALHC stock to plunge 16.7% in a single day, marking its worst performance since February 2024.

Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who have suffered losses are encouraged to contact the firm.

Hagens Berman is investigating Alignment Healthcare (ALHC) following whistleblower allegations that the company engaged in accounting irregularities, misclassifying operating expenses as capital expenditures to inflate EBITDA and financial metrics. The disclosure caused ALHC stock to plunge 16.7% in a single day, marking its worst performance since February 2024.

Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following the report. The firm is also investigating Jefferies Financial Group and Unicycive Therapeutics for similar violations.

Law firm Johnson Fistel announced an investigation into Alignment Healthcare (NASDAQ: ALHC) following a whistleblower lawsuit filed by a former executive alleging the company manipulated its finances to boost stock price and executive compensation. The firm is investigating whether the company complied with federal securities laws and is seeking investors who suffered losses.

Joseph Konowiecki, vice chairman of Alignment Healthcare, sold 25,000 shares on June 26 for $575,000, reducing his direct holdings by 2.2%. While the sale aligns with his historical trading pattern and occurs under a pre-filed trading plan, the timing coincides with his recent step down from chairman and follows a pattern of executive selling over the past year. However, insider sales are predictive of stock declines less than half the time, and investors should weigh this against other company fundamentals.

Alignment Healthcare's EVP Joseph Konowiecki sold 25,000 shares worth $550,000 under a pre-arranged trading plan, representing just 2.1% of his holdings. The article argues this routine sale shouldn't concern investors, as the company is executing well in the Medicare Advantage market with strong Q1 results showing 33.3% revenue growth, 30.9% membership growth, and a swing to profitability with management raising full-year guidance.

Alignment Healthcare released its 2025 Impact Report demonstrating significant reductions in high-cost healthcare utilization among its Medicare Advantage members, including 34% fewer emergency room visits and inpatient admissions, and 44% fewer skilled nursing facility admissions compared to 2019 Medicare fee-for-service benchmarks. The company attributes these outcomes to its proactive care model featuring AI-powered technology (AVA) and in-home/virtual care programs, while maintaining 100% of members in 4-Star or higher rated plans.

Alignment Healthcare Inc. (ALHC) will be added to the S&P SmallCap 600 index effective May 14, 2026, replacing Sun Country Airlines Holdings (SNCY). The replacement follows Allegiant Travel Co.'s acquisition of Sun Country Airlines, which is expected to close soon.

The Centers for Medicare & Medicaid Services announced a 2.48% increase in 2027 Medicare Advantage capitation rates, exceeding initial expectations of 0.09%. The boost amounts to over $13 billion in additional payments and reflects a 4.98% increase when accounting for risk score trends. CMS retained the 2024 risk adjustment model, providing greater rate predictability for insurers. Major healthcare stocks surged on the positive announcement.

Alignment Healthcare (NASDAQ: ALHC) announced a secondary public offering of 13.2 million shares priced at $19.46 per share by an affiliate of General Atlantic. The company will not receive proceeds from the sale. The offering is expected to close on March 4, 2026, with J.P. Morgan serving as underwriter.

The Centers for Medicare & Medicaid Services (CMS) proposed a 2027 Medicare Advantage payment increase of only 0.09%, significantly below Wall Street's expectations of 4-6%. This modest growth announcement triggered sharp declines in major health insurer stocks, with UnitedHealth, Humana, and CVS Health leading the losses. The CMS emphasized program sustainability and payment accuracy through updated risk adjustment models.